Maria Castro

Maria Castro is a Professor in the Department of Neurosurgery at the University of Michigan Medical School, where she leads groundbreaking research in neuro-oncology with a specific focus on brain tumor treatment and glioblastoma research. Her work bridges laboratory science with clinical applications, developing innovative therapies for some of the most challenging brain cancers.

Dr. Castro's research primarily centers on developing novel therapeutic approaches for glioblastoma and other malignant brain tumors. Her work spans multiple cutting-edge areas including nanoparticle therapy for brain tumors, oncolytic virotherapy, epigenetic reprogramming in gliomas, and artificial intelligence applications in neurosurgery. She has made significant contributions to understanding how cholesterol metabolism affects glioma progression and has developed HDL nanodisc technology to target brain tumors. Her research on oncolytic viruses has opened new avenues for cancer immunotherapy, while her work on FastGlioma represents a major breakthrough in intraoperative brain tumor detection technology.

Analysis of Dr. Castro's recent publications reveals a strong focus on translating basic science discoveries into clinical applications. Her work spans multiple disciplines including neuro-oncology, cancer immunology, nanomedicine, epigenetics, and artificial intelligence. A common thread throughout her research is the development of targeted therapies that address specific molecular vulnerabilities in brain tumors, particularly focusing on IDH-mutant gliomas and pediatric high-grade gliomas. Her publications demonstrate increasing collaboration with interdisciplinary teams including engineers, computer scientists, and clinicians to develop comprehensive treatment approaches.

Dr. Castro actively collaborates with numerous researchers, most notably with Dr. Pedro Lowenstein on oncolytic virus therapies and with Dr. Anna Schwendeman on nanodisc technology. Her work has attracted significant research funding for developing novel brain tumor treatments, particularly in the areas of targeted drug delivery systems and immunotherapies. She is involved in multiple translational research projects aiming to move laboratory discoveries into clinical trials for brain tumor patients.

Her laboratory operates at the intersection of multiple research areas, with teams focused on nanomedicine development, viral vector engineering, AI applications in neurosurgery, and molecular characterization of brain tumors. The lab utilizes sophisticated mouse models of glioma and works closely with clinicians to ensure research is clinically relevant. Recent work has expanded into studying the tumor microenvironment and how immune cells interact with brain tumor cells, opening new possibilities for combination therapies.